Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

2.

EBCC: European Breast Cancer Conference

3.

Germline Variants Predict Lobular Breast Cancer Recurrence

4.

A Win for Molecularly Guided Therapy for Cancer of Unknown Primary

5.

Joe Biden has prostate cancer with bone spread. An oncologist explains what you need to know


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot